GLP-1 receptor agonist peptides, primarily used for diabetes and obesity, show early promise for managing psoriasis and psoriatic arthritis by reducing both inflammation and metabolic dysfunction.
Dual metabolic + immune benefitsGLP-1 receptor agonist peptides may address both the metabolic dysfunction and the inflammatory pathways driving psoriasis and psoriatic arthritis in obese patients
What the researchers found
GLP-1 receptor agonists, including dual GLP-1/GIP agonists like tirzepatide, demonstrate benefits beyond blood sugar control — including weight loss, improved metabolic health, and potential immune response modulation. Recent studies suggest they may help manage psoriasis and psoriatic arthritis in patients with obesity by reducing inflammation and addressing metabolic abnormalities like insulin resistance and hyperlipidemia. However, the evidence supporting their use specifically for psoriasis and psoriatic arthritis remains limited.
Why it matters
Psoriasis and psoriatic arthritis affect millions of people, and obesity significantly worsens both conditions while making standard treatments less effective. If GLP-1 peptide agonists can simultaneously address weight, metabolic dysfunction, and autoimmune inflammation, they could fill a major unmet need — particularly for the large proportion of psoriasis patients who also have metabolic syndrome. This represents a potential paradigm shift from treating these conditions in isolation to addressing the metabolic-immune axis as a whole.
How the study worked
This is a conference report summarizing a presentation given at the GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) 2024 annual meeting. It reviews the current state of evidence on GLP-1 receptor agonists as potential treatments for psoriasis and psoriatic arthritis, particularly in patients with concurrent obesity.
What this study cannot tell us
This is a conference summary, not a systematic review or original research. It does not present new clinical data. The evidence for GLP-1 agonists specifically treating psoriasis and psoriatic arthritis is acknowledged as limited. No specific clinical trial results, patient numbers, or effect sizes are provided in the abstract. The dual mechanism (anti-inflammatory vs. weight-loss-mediated improvement) has not been clearly separated.
How to read the evidence
This is a conference presentation summary published in a rheumatology journal supplement. It provides an expert overview of the current evidence landscape but does not present new data. The evidence for GLP-1 agonists in psoriatic disease is acknowledged as early and limited.
When this study was published
Published in 2025 based on the GRAPPA 2024 annual meeting, this is a very current summary of an actively evolving area of research at the intersection of metabolic and autoimmune disease.
The bigger picture
The growing recognition that metabolic health and autoimmune inflammation are deeply intertwined is reshaping how clinicians approach diseases like psoriasis and psoriatic arthritis. GLP-1 receptor agonist peptides, which are already transforming diabetes and obesity care, represent one of the most exciting crossover opportunities in medicine — a single class of peptide drugs that could address the metabolic, inflammatory, and immune dimensions of multiple chronic conditions simultaneously.
Questions still open
- Do GLP-1 receptor agonists directly reduce psoriatic inflammation, or do improvements come primarily from weight loss and metabolic normalization?
- Which GLP-1 agonist — semaglutide, tirzepatide, or others — shows the most promise for psoriatic disease, and at what doses?
- Could combining GLP-1 agonists with existing psoriasis biologics produce additive or synergistic benefits?
Common questions
How could a diabetes drug help with psoriasis?
Are GLP-1 agonists approved for treating psoriasis or psoriatic arthritis?
Read the original research
What Clinicians Need to Know About Glucagon-like Peptide 1 Agonists.
The Journal of rheumatology, 52(Suppl 3), 52-54
Citation
da Silva, Dimitri Luz Felipe; Singla, Shikha; Mease, Philip J. (2025). What Clinicians Need to Know About Glucagon-like Peptide 1 Agonists.. The Journal of rheumatology, 52(Suppl 3), 52-54. https://doi.org/10.3899/jrheum.2025-0531